Summary:
- This article discusses the approval granted by the Central Drugs Standard Control Organization (CDSCO) in India for the use of the drug durvalumab in combination with FLOT chemotherapy.
- Durvalumab is an immunotherapy drug that helps the body's immune system fight cancer cells, and it has been approved for use in treating certain types of advanced or metastatic gastric or gastroesophageal junction cancer.
- The FLOT chemotherapy regimen is a combination of several chemotherapy drugs that are used to treat gastric and esophageal cancers, and the approval of this combination therapy provides a new treatment option for patients with these types of cancers.